Evidence map›Paper›PMID 33589697›Full record

ArticleScientific reports2021

Disturbance of cellular homeostasis as a molecular risk evaluation of human endothelial cells exposed to nanoparticles.

Paulina Wigner, Krzysztof Zielinski, Sylwia Michlewska, Paulina Danielska, Agnieszka Marczak, Eduardo Junior Ricci, Ralph Santos-Oliveira, Marzena Szwed

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Biosynthesized Silver Nanoparticles fromCurrent pharmaceutical biotechnology · 2024
    Article
  9. [Drug delivery · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Paulina Wigner *Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Krzysztof Zielinski *Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Sylwia MichlewskaLaboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.ORCID 0000-0002-8952-469X
Paulina DanielskaDepartment of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Agnieszka MarczakDepartment of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.ORCID 0000-0003-3439-9032
Eduardo Junior RicciLaboratory of Nanodrugs, Faculty of Pharmacy, Rio de Janeiro Federal University, Rio de Janeiro, Brazil.ORCID 0000-0002-2550-696X
Ralph Santos-OliveiraLaboratory of Nanoradiopharmaceuticals, Research Group of Nano-Radiopharmaceuticals and Novel Radiopharmaceuticals, Zona Oste State University, Rio de Janeiro, Brazil.ORCID 0000-0002-7221-6404
Marzena SzwedDepartment of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland. marzena.szwed@biol.uni.lodz.pl.ORCID 0000-0002-2102-3741
University of Łódź · PLNuclear Engineering Institute · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even though application of nanoparticles in medicine seems to provide unique solutions for drug delivery and diagnosis diseases, understanding interactions between nanoscale materials and biological systems is imperative. Therefore, this study determined the effect of different types of nanoparticles (NPs) on human endothelial cells and examined the types of toxicity responses they can induce. Four different types of NPs were tested (PLA/MMT/TRASTUZUMAB, PLA/EDTMP, PLGA/MDP, and Pluronic F127 MICELLES), representing three putative areas of application: anticancer therapy, scintigraphy, and cosmetology. The experiments were performed on immortalized human umbilical vein endothelial cells (HUVEC-STs). Light contrast phase microscopy as well as cell viability assays showed that only Pluronic F127 MICELLES decreased the number of HUVEC-STs in contrast to PLA/MMT/TRASTUZUMAB, PLA/EDTMP, and PLGA/MDP NPs, which altered cell morphology, but not their confluency. The tested NPs induced not only DNA strand-breaks and alkali-labile sites, but also internucleosomal DNA fragmentation, visualized as a DNA ladder pattern typical of apoptosis. Moreover, generation of free radicals and subsequent mitochondrial membrane potential collapse showed the significance of free radical production during interactions between NPs and endothelial cells. High concentrations of NPs had different degrees of toxicity in human endothelial cells and affected cell proliferation, redox homeostasis, and triggered mitochondrial dysfunction.

Indexed as

BiomarkersHomeostasisNanoparticlesApoptosisCell LineCells, CulturedCell SurvivalChemical PhenomenaDNA DamageDNA FragmentationDrug CarriersHumansHuman Umbilical Vein Endothelial CellsMitochondriaOxidative StressParticle SizeBiomarkersDrug Carriers

Identifiers

PMID33589697
PMCPMC7884700
OpenAlexW3132362010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.